Similar articles

• Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig.

  Hay DW, Muccitelli RM, Vickery-Clark LM, Novak LS, Osborn RR, Gleason JG, Yodis LA, Saverino CM, Eckardt RD, Sarau HM, et al. Hay DW, et al. Pulm Pharmacol. 1991;4(3):177-89. doi: 10.1016/0952-0600(91)90009-r. Pulm Pharmacol. 1991. PMID: 1668219
• Pharmacologic profile of SK&F 104353, a novel, highly potent and selective peptidoleukotriene antagonist.

  Wasserman MA, Torphy TJ, Hay DW, Muccitelli RM, Tucker SS, Wilson KA, Osborn RR, Vickery-Clark L, Hall RF, Erhard KF, et al. Wasserman MA, et al. Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:532-5. Adv Prostaglandin Thromboxane Leukot Res. 1987. PMID: 2821765 No abstract available.
• Pharmacologic profile of SK&F 104353: a novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways.

  Hay DW, Muccitelli RM, Tucker SS, Vickery-Clark LM, Wilson KA, Gleason JG, Hall RF, Wasserman MA, Torphy TJ. Hay DW, et al. J Pharmacol Exp Ther. 1987 Nov;243(2):474-81. J Pharmacol Exp Ther. 1987. PMID: 2824747
• Clinical experience with MK-571. A potent and specific LTD4 receptor antagonist.

  Margolskee DJ. Margolskee DJ. Ann N Y Acad Sci. 1991;629:148-56. doi: 10.1111/j.1749-6632.1991.tb37972.x. Ann N Y Acad Sci. 1991. PMID: 1659276 Review. No abstract available.
• A brief review of preclinical and clinical studies with LY171883 and some comments on newer cysteinyl leukotriene receptor antagonists.

  Fleisch JH, Cloud ML, Marshall WS. Fleisch JH, et al. Ann N Y Acad Sci. 1988;524:356-68. doi: 10.1111/j.1749-6632.1988.tb38558.x. Ann N Y Acad Sci. 1988. PMID: 2837970 Review. No abstract available.